Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
05/05/2026 12:52
May 5 (Reuters) - Sensei Biotherapeutics Inc SNSE.O: SENSEI BIOTHERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 TRIAL OF PIKTOR IN HR+/HER2- ADVANCED BREAST CANCER SENSEI BIOTHERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 TRIAL OF PIKTOR IN HR+/HER2- ADVANCED BREAST CANCER Source text: ID:nBwNM3qwa Further company coverage: SNSE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments